I'm less optimistic and think this is a red herring, I mean big pharma acquire clinical phase 2 success drugs every day of the week, why is this one awaiting FDA approval based on merely updated instructions still deemed insufficiently attractive? Clearly I'm missing something.
Sofdra - Post approval royalties, costs and earnings, page-29
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
-0.005(1.72%) |
Mkt cap ! $448.9M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 28.0¢ | $1.405M | 4.899M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 200490 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 345394 | 4 |
View Market Depth
| Last trade - 16.10pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
28.3¢ |
Change
-0.005 ( 3.68 %) |
||||
| Open | High | Low | Volume | ||
| 29.5¢ | 29.5¢ | 28.0¢ | 2039177 | ||
| Last updated 15.59pm 04/06/2024 ? | |||||
| BOT (ASX) Chart |